Australia - Inggris - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amitriptyline hydrochloride, quantity: 14 mg; chlordiazepoxide, quantity: 5 mg - tablet - excipient ingredients: microcrystalline cellulose; silicon dioxide; pregelatinised maize starch; croscarmellose sodium; quinoline yellow aluminium lake; brilliant blue fcf aluminium lake; purified water; magnesium stearate; sodium lauryl sulfate; hypromellose; hyprolose; titanium dioxide; macrogol 400; sunset yellow fcf aluminium lake; macrogol 8000

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amitriptyline hydrochloride, quantity: 27.98 mg; chlordiazepoxide, quantity: 10 mg - tablet - excipient ingredients: microcrystalline cellulose; silicon dioxide; pregelatinised starch; croscarmellose sodium; purified water; magnesium stearate; sodium lauryl sulfate; titanium dioxide; hypromellose; hyprolose; purified talc; macrogol 400; calcium sulfate; macrogol 8000

Afrika Selatan - Inggris - South African Health Products Regulatory Authority (SAHPRA)

mylan pharmaceuticals (pty) ltd - #n/a - not indicated - none

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.688 mg; metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; sodium fumarate; sodium stearyl phthalamate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - sitagliptin/metformin mylan (sitagliptin hydrochloride monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate., [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.688 mg; metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; sodium fumarate; sodium stearyl phthalamate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; macrogol 4000; polyvinyl alcohol - sitagliptin/metformin mylan (sitagliptin hydrochloride monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate., [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.688 mg; metformin hydrochloride, quantity: 1000 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; sodium fumarate; sodium stearyl phthalamate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - sitagliptin/metformin mylan (sitagliptin hydrochloride monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate., [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - betahistine dihydrochloride, quantity: 16 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; mannitol; citric acid monohydrate; purified talc - meniere's syndrome as defined by the following core symptoms: - vertigo (with nausea/vomiting): - hearing loss (hardness of hearing): - tinnitus.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 392.3 mg (equivalent: cefaclor, qty 375 mg) - tablet, modified release - excipient ingredients: mannitol; hypromellose; hyprolose; methacrylic acid copolymer; stearic acid; magnesium stearate; propylene glycol; purified talc; colour - karlor cd is indicated for the treatment of the following types of infections caused by susceptible organisms, in adults and children aged 12 years or older: acute bronchitis and acute exacerbations of chronic bronchitis; upper respiratory infections, including phryngitis, tonsillitis and acute bacterial sinusitis; community-acquired pneumonia of mild to moderate severity (excluding atypical pneumonia); symptomatic lower urinary tact infections, including cystitis; skin and skin structure infections. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. karlor cd is generally effective in the eradication of streptococci from the oropharynx; however, substantial data establishing the efficacy of karlor cd in the subsequent prevention of rheumatic fever are not available. 2. bacteriological studies to determine the causative organism and its susceptibility to cefaclor should be performed. therapy may be started

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 53.72 mg/ml (equivalent: cefaclor, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; tapioca starch; erythrosine; sucrose; flavour - aclor is indicated for the treatment of the following types of infections caused by or likely to be caused by susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. aclor appears to be as effective as phenoxymethyl penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of aclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 26.86 mg/ml (equivalent: cefaclor, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; tapioca starch; erythrosine; sucrose; flavour - aclor is indicated for the treatment of the following types of infections caused by or likely to be caused by susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. aclor appears to be as effective as phenoxymethyl penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of aclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.